AvertD

05/27/2025

AvertD® stands apart as the first and only U.S. Food and Drug Administration-authorized genetic test for assessing Opioid Use Disorder (OUD) risk. Backed by studies using DSM-5 clinical diagnoses, AvertD® provides healthcare providers with an objective and clinically validated tool to guide decisions for patients prescribed short-term oral opioids.

This is the gold standard of genetic testing, setting a new benchmark for innovation in opioid safety. Learn how AvertD® can enhance shared decision-making: https://avertdtest.com/

05/21/2025

Those with higher genetic risk for opioid use disorder can be unsuspecting victims of addiction. Genetics is an important piece of the puzzle—and AvertD, the first U.S. Food and Drug Administration-approved genetic test for assessing elevated risk of OUD, is helping providers see the whole picture.

Learn more: https://avertdtest.com/

05/19/2025

As of 2022, over 1 billion people are living with obesity — that’s one in eight people — with the prevalence of worldwide obesity more than tripling between 1975 and 2022. The World Obesity Federation projects the global economic impact of overweight and obesity will exceed $4 trillion annually by 2035. This is why SOLVD Health is developing a test to determine super responders and non-responders of individual GLP-1s​ to help with better-targeted outcomes and patient stratification​ and aid in more personalized and effective management of chronic conditions​.

“At SOLVD Health, we’re focused on discovering and developing novel technologies that identify an individual’s risk of developing a disease. Through the discovery and conversion of biological signals into predictive, contextual health insights, we are empowering patients and their healthcare providers with objective, actionable information to prevent disease,” says SOLVD Health CEO Keri Donaldson.

Learn about the work SOLVD Health is doing to improve patient outcomes: https://solvdhealth.com/pipeline/

05/15/2025

Opioid Use Disorder (OUD) is preventable, and AvertD is designed to help. AvertD is the first and only FDA-authorized genetic test that uses patient DNA to determine whether they have a specific set of genetic variants that may be associated with an elevated genetic risk of developing OUD. By identifying at-risk patients upfront, we can change the trajectory of opioid misuse before it begins.

Learn more about how AvertD is transforming opioid safety: https://avertdtest.com/

05/12/2025

SOLVD Health welcomes diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support SOLVD Health’s continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform.

Learn more about the latest additions to the board: https://solvdhealth.com/news/solvd-health-appoints-mike-aicher-and-vince-cebula/

04/29/2025

To recognize Laboratory Professionals Week, SOLVD Health honored the incredible work of its lab professionals with a bit of friendly competition and a lot of good food! From our Lab Olympics competition to a great team lunch, it’s been a great reminder of the dedication, talent, and teamwork that drive everything SOLVD Health does.

Thank you to SOLVD Health’s lab team for your precision, passion, and commitment to improving patient care every day!

📸 Swipe through for some of our favorite moments from the week.

01/16/2025

~1 in 6 patients who have an Elevated Genetic Risk may develop OUD after taking oral opioids for acute pain. AvertD® identifies genetic factors associated with an elevated risk of developing opioid use disorder (OUD). This FDA-approved test is rooted in rigorous research, providing healthcare providers with actionable insights to guide safer, more personalized pain management decisions.

Understanding an elevated risk doesn’t mean a patient will develop OUD — it’s about empowering patients and providers to make informed choices before opioids are prescribed.

Learn more about the science behind AvertD® and how it’s shaping the future of preventive care: https://avertdtest.com/

01/13/2025

21M surgical procedures are at high risk for postoperative opioid misuse, with ~10% of patients misusing or becoming addicted to opioids post-surgery.

From a quick cheek swab to actionable insights, AvertD® makes it easy for healthcare providers to assess a patient’s risk for developing opioid use disorder (OUD). Swipe through to see how it works and supports safe, more informed pain management decisions.

Learn more: https://avertdtest.com/

01/12/2025

Today, we celebrate the vital role pharmacists play in safeguarding patient health. Pharmacists can be a first line of defense in ensuring patients understand the risks associated with opioid use and the importance of safer pain management options.

Their dedication to educating patients and supporting informed healthcare decisions is invaluable in the fight against the opioid crisis.

Thank you to pharmacists everywhere for your commitment to improving lives and advancing health!

01/09/2025

Approximately 1 in 16 patients prescribed opioids will use them long-term, significantly increasing their risk for opioid use disorder (OUD). Understanding individual risk is a critical step in preventing opioid misuse and promoting safer pain management.

With patient health outcomes at the forefront, AvertD® empowers healthcare providers to personalize care, support informed decision-making, and help protect patients from potential harm.

Learn more about how AvertD® is shaping the future of personalized care: https://avertdtest.com/

01/07/2025

Recent CDC data indicates a significant decline in U.S. drug overdose deaths, with a nearly 17% drop reported in the 12 months ending in June 2024, totaling 93,087 fatalities. This marks the first time since 2020 that annual overdose deaths have fallen below 100,000. While this trend is encouraging, the opioid crisis remains a critical public health challenge.

Continued efforts in prevention, treatment, and education are essential to sustain and accelerate this progress. AvertD® is proud to be empowering patients and providers with actionable insights that could prevent opioid use disorder.

NPR shares more details about the recent developments: https://www.npr.org/2024/11/14/nx-s1-5191743/overdose-deaths-drop-fentanyl-opioid-crisis

A new CDC report shows at least 16,000 lives were saved over a 12-month period. Experts say the U.S. is experiencing the biggest drop in fatal overdoses seen since the opioid crisis began in the 90s.

01/02/2025

As many kick off the year with fitness goals, we are reminded and mindful of the risks associated with injuries that can occur while being active. For some, significant injuries could lead to an opioid prescription — and in certain cases, there is potential for development of opioid use disorder (OUD).

That’s why understanding genetic risk is so important. AvertD® empowers patients and healthcare providers with the information they need to make safe, informed decisions about pain management.

Find out more about AvertD®: https://avertdtest.com/